Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07689539
PHASE3

Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy

Official title: A Phase 3, Multicenter, Open-Label, Randomized, Controlled Trial of DN022150 Monotherapy Versus Investigator's Choice Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

360

Start Date

2026-09

Completion Date

2028-12

Last Updated

2026-07-08

Healthy Volunteers

No

Interventions

DRUG

DN022150

iv QW 28-day/cycle

DRUG

Chemotherapy

Investigator's Choice of Chemotherapy: nal-IRI + 5-FU/LV, AG, or S-1